Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Bristol-Myers Squibb CompanyNYSE: BMY

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income grows, but more slowly than its trailing trend

Q2 FY2026 operating income of $4.03B rose 6.7% year over year, behind the +39.1% change in trailing-twelve-month operating income. Sequentially, it rose 19.6% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.

Context

  • Operating income amounted to 28.5% of revenue in FY2025, up 16.3 pp from a year earlier.
  • Operating income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 19 analysts of $16.72B (+21.8%) for the fiscal year ending Dec 2026, a slowdown from the +133.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.03B+19.6% QoQ
Last fiscal yearDec 2025
$13.72B+133.1% YoY
LTMJun 2026
$13.84B+39.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.7%-18.3%-25.0 pp
1 year+133.1%+21.8%-111.3 pp
3-year CAGR+14.7%+0.8%-13.8 pp
5-year CAGR-0.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
13.72B USD
Year-over-year change
+133.1%
4-year CAGR
+12.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.1% is the 4th highest of 11, against a peer median of +10.5%.
  • Operating income amounts to 28.1% of revenue for BMY, versus a peer median of 26.2%.
BMY Competitors
Operating Income for BMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$39.61B USD+76.5%+50.8%49.7%
JNJJohnson & JohnsonLTM Sep 2026$25.53B USD+6.2%+6.8%25.7%
ABBVAbbVie Inc.LTM Sep 2026$23.46B USD+159.5%+3.5%35.5%
PFEPfizer Inc.LTM Jun 2026$17.02B USD+2.2%-23.0%26.7%
NVSNovartis AGLTM Jun 2026$16.99B USD+1.8%+29.0%30.5%
AZNAstraZeneca PLCLTM Sep 2026$14.71B USD+14.9%+54.1%23.7%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$13.84B USD+39.1%+14.7%28.1%
AMGNAmgen Inc.LTM Jun 2026$12.65B USD+54.6%+3.7%33.2%
MRKMerck & Co., Inc.LTM Jun 2026$11.06B USD-48.3%+8.7%16.7%
GSKGSK plcLTM Jun 2026£6.87B GBP+34.1%+9.0%20.7%
GILDGilead Sciences, Inc.LTM Jun 2026-$1.49B USD-118.5%+16.9%4.9%
Peer median (excluding BMY) —+10.5%+8.9%26.2%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.